Literature DB >> 19095720

Pinoline may be used as a probe for CYP2D6 activity.

Xi-Ling Jiang1, Hong-Wu Shen, Ai-Ming Yu.   

Abstract

Pinoline, 6-methoxy-1,2,3,4-tetrahydro-beta-carboline, is a serotonin analog that selectively inhibits the activity of monoamine oxidase-A and shows antidepressant activity. Our previous study using a panel of recombinant cytochrome P450 (P450) enzymes suggests that pinoline O-demethylation may be selectively catalyzed by polymorphic CYP2D6. The current study, therefore, aimed to delineate the impact of CYP2D6 status on pinoline metabolism. Enzyme kinetic studies using recombinant CYP2D6 allelic isozymes revealed that CYP2D6.2 exhibited 5-fold lower enzyme efficiency (V(max)/K(m)) toward pinoline compared with CYP2D6.1, and CYP2D6.10 did not show any catalytic activity. Inhibition study showed that quinidine (1 microM) completely blocked pinoline O-demethylase activity in human liver microsomes, whereas other P450 isoform-selective inhibitors had no or minimal effects. Pinoline O-demethylase activities in 10 human liver microsomes showed significantly strong correlation with bufuralol 1'-hydroxylase activities (R(2)=0.93; p<0.0001) and CYP2D6 contents (R(2)=0.82; p=0.005), whereas no appreciable correlations with enzymatic activities of other P450 enzymes were found. Furthermore, we compared pinoline urinary metabolic ratio (pinoline/6-hydroxy-1,2,3,4-tetrahydro-beta-carboline) between CYP2D6-humanized and wild-type control mice after intraperitoneal injection of pinoline (30 mg/kg). Results indicated that the two genotyped mice were clearly distinguished by pinoline metabolic ratio (mean +/- S.D.), which was much higher in wild-type mice (0.29+/-0.19, n=4) than in CYP2D6-humanized transgenic mice (0.0070+/-0.0048, n=4). Our findings suggest that pinoline O-demethylation is governed by CYP2D6 status, and pinoline, at a proper concentration or dose, may be a good probe to evaluate CYP2D6 activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19095720      PMCID: PMC2680515          DOI: 10.1124/dmd.108.025056

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

1.  Metabolism of 6-methoxytetrahydro- -carboline in rats.

Authors:  B T Ho; D Taylor; K E Walker; W McIsaac
Journal:  Xenobiotica       Date:  1972-07       Impact factor: 1.908

2.  The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.

Authors:  J Corchero; C P Granvil; T E Akiyama; G P Hayhurst; S Pimprale; L Feigenbaum; J R Idle; F J Gonzalez
Journal:  Mol Pharmacol       Date:  2001-12       Impact factor: 4.436

3.  Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.

Authors:  Aiming Yu; Byron M Kneller; Allan E Rettie; Robert L Haining
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

4.  Increased levels of oxidatively damaged DNA induced by chromium(III) and H2O2: protection by melatonin and related molecules.

Authors:  W Qi; R J Reiter; D X Tan; L C Manchester; A W Siu; J J Garcia
Journal:  J Pineal Res       Date:  2000-08       Impact factor: 13.007

5.  Effects of the beta-carbolines, harmane and pinoline, on insulin secretion from isolated human islets of Langerhans.

Authors:  E Jane Cooper; Alan L Hudson; Christine A Parker; Noel G Morgan
Journal:  Eur J Pharmacol       Date:  2003-12-15       Impact factor: 4.432

6.  Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.

Authors:  Ai-Ming Yu; Jeffrey R Idle; Tomas Herraiz; Adrian Küpfer; Frank J Gonzalez
Journal:  Pharmacogenetics       Date:  2003-06

Review 7.  Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.

Authors:  Ai-Ming Yu; Jeffrey R Idle; Frank J Gonzalez
Journal:  Drug Metab Rev       Date:  2004-05       Impact factor: 4.518

8.  Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymes.

Authors:  Wei-Yan Zhang; You-Bin Tu; Robert L Haining; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2008-10-06       Impact factor: 3.922

9.  Endogenous and dietary indoles: a class of antioxidants and radical scavengers in the ABTS assay.

Authors:  Tomas Herraiz; Juan Galisteo
Journal:  Free Radic Res       Date:  2004-03

Review 10.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Authors:  Ulrich M Zanger; Sebastian Raimundo; Michel Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-15       Impact factor: 3.000

View more
  14 in total

Review 1.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice.

Authors:  Hong-Wu Shen; Ai-Ming Yu
Journal:  Drug Metab Lett       Date:  2009-12

3.  Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.

Authors:  Hong-Wu Shen; Chao Wu; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2010-03-03       Impact factor: 5.858

4.  Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.

Authors:  Jessica Tay-Sontheimer; Laura M Shireman; Richard P Beyer; Taurence Senn; Daniela Witten; Robin E Pearce; Andrea Gaedigk; Cletus L Gana Fomban; Justin D Lutz; Nina Isoherranen; Kenneth E Thummel; Oliver Fiehn; J Steven Leeder; Yvonne S Lin
Journal:  Pharmacogenomics       Date:  2014-12       Impact factor: 2.533

Review 5.  Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models.

Authors:  Xi-Ling Jiang; Frank J Gonzalez; Ai-Ming Yu
Journal:  Drug Metab Rev       Date:  2010-09-21       Impact factor: 4.518

6.  Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder.

Authors:  M S Zastrozhin; A V Efimova; VYu Skryabin; V V Smirnov; A E Petukhov; E P Pankratenko; S A Pozdniakov; E V Kaverina; D A Klepikov; E A Grishina; K A Ryzhikova; I V Bure; E A Bryun; D A Sychev
Journal:  Psychopharmacol Bull       Date:  2021-11-03

7.  Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Donald E Mager; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2013-02-07       Impact factor: 3.922

8.  Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.

Authors:  M S Zastrozhin; VYu Skryabin; VYu Smirnov; A K Zastrozhina; E V Kaverina; D A Klepikov; E A Grishina; K A Ryzhikova; I V Bure; E A Bryun; D A Sychev
Journal:  Psychopharmacol Bull       Date:  2021-01-12

9.  Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder.

Authors: 
Journal:  Psychopharmacol Bull       Date:  2020-07-23

10.  The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder.

Authors: 
Journal:  Psychopharmacol Bull       Date:  2020-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.